Clinical Trials Search Tool

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis

Disease/Condition: Atopic Dermatitis

Location: Gresham

Ages: 2 – 12 years of age

Enrollment Opens: 09-22-2021

Enrollment Closes: TBD


Randomized (2:2:1), double-blind, VC period (8 weeks) followed by
an LTS period (44 weeks) and a 30-day safety follow-up period after
the last application of study drug. In the LTS period, participants
initially randomized to vehicle cream will be rerandomized (1:1) in a
blinded manner to ruxolitinib cream 0.75% or 1.5%, and participants
initially randomized to an active treatment group will continue in the
same treatment group.

Study ID: INCB 18424-305

To Enroll: Contact Cyn3rgy Research at; 503-907-2179 ext. 4 or visit us on the web at

Posted by: Cyn3rgy Research |